Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20216162 | 0.95 | MGLL (0.37) | PTGS1PTGS2MGLLFAAH | |
| SCHEMBL22420047 | 0.93 | MGLL (0.40) | PTGS1PTGS2MGLLFAAH | |
| SCHEMBL24690695 | 0.89 | GMNN (0.30) | MGLL | |
| SCHEMBL12313634 | 0.83 | GMNN (0.33) | MGLL | |
| SCHEMBL18897244 | 0.83 | MGLL (0.36) | PTGS1PTGS2MGLLFAAH | |
| SCHEMBL18469617 | 0.82 | MGLL (0.39) | PTGS1PTGS2MGLLFAAH | |
| SCHEMBL21108746 | 0.81 | MGLL (0.37) | PTGS1PTGS2MGLLFAAH | |
| SCHEMBL18737355 | 0.80 | MGLL (0.40) | PTGS1PTGS2MGLLFAAH | |
| SCHEMBL18737513 | 0.80 | MGLL (0.40) | PTGS1PTGS2MGLLFAAH | |
| SCHEMBL19176551 | 0.80 | MGLL (0.40) | PTGS1PTGS2MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PTGS1 3720/4885PTGS2 2603/4885MGLL 616/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | PTGS1 2252/4885PTGS2 1705/4885MGLL 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.